Showing 1831-1840 of 2050 results for "".
- Johnson & Johnson Vision Launches New Eye Care Solutions and Showcases Latest Clinical Data at ESCRS 2020 Virtual Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-launches-new-eye-care-solutions-and-showcases-latest-clinical-data-at-escrs-2020-virtual-annual-meeting/2478335/Johnson & Johnson Vision will launch Tecnis Synergy Toric II IOL with the Tecnis Simplicity Delivery System, a continuous-range-of-vision IOL, at the upcoming virtual European Society of Cataract and Refractive Surgeons (ESCRS) 2020 Annual Meeting, October 2-4. In addition, the company
- Johnson & Johnson Vision to Introduce Tecnis Synergy Toric II IOL and Catalys System cOS 6.0 Software at the ESCRS 2020https://modernod.com/news/johnson-johnson-vision-to-introduce-tecnis-synergy-toric-ii-iol-and-catalys-system-cos-6-0-software-at-the-escrs-2020/2478331/Johnson & Johnson Vision announced the availability of two new developments in the treatment of cataracts for patients with astigmatism in Europe. Tecnis Synergy Toric II IOL with Tecnis Simplicity Delivery System is a continuous-range-of-vision lens engineered for rotational stability, which
- Retina Consultants of America Announces New Alliancehttps://modernod.com/news/retina-consultants-of-america-announces-new-alliance/2478304/VitreoRetinal Surgery PA, based in Minnesota, has joined Retina Consultants of America (RCA). This is the sixth retina specialty practice to join RCA as it continues to expand the company’s footprint across the United States, including California Retina Consultants, Retina Consultants of Housto
- Visible Genomics Launches DNA Age-Related Macular Degeneration Testinghttps://modernod.com/news/visible-genomics-launches-dna-age-related-macular-degeneration-testing/2478264/Visible Genomics, a Chicago-area genetics testing company, has announced the launch of a new noninvasive genetic eye test that the company says determines a patient’s likelihood of contracting age-related macular degeneration (AMD). While it’s estimated that up to 70% of AMD cases are due
- Alimera Sciences Announces Enrollment of First Patient in NEW DAY Clinical Trial to Evaluate Iluvien as Baseline Therapy for DMEhttps://modernod.com/news/alimera-sciences-announces-enrollment-of-first-patient-in-new-day-clinical-trial-to-evaluate-iluvien-as-baseline-therapy-for-dme/2478243/Alimera Sciences announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone ac
- Injectsense Receives Breakthrough Device Program Designation From FDA for IOP Monitoring Systemhttps://modernod.com/news/injectsense-receives-breakthrough-device-program-designation-from-fda-for-iop-monitoring-system/2478233/Injectsense announced it has received a breakthrough device program (BDP) designation from the FDA for its chronic continuous IOP monitoring system for glaucoma patients. The company’s IOP Connect system is based on a long-term implantable sensor, smaller than a grain of rice, that is delivered t
- AstraZeneca Kicks Off Phase 3 Study of COVID-19 Vaccine AZD1222 in the UShttps://modernod.com/news/astrazeneca-kicks-off-phase-3-study-of-covid-19-vaccine-azd1222-in-the-us/2478229/AstraZeneca announced the start of a phase 3 study in the US investigating its experimental COVID-19 vaccine AZD1222 in up to 30,000 adults aged 18 years or over. Subjects in the trial, called D8110C00001, will be randomized to receive two doses of either AZD1222 or a saline control, 4 weeks apar
- Americans See Hospitals as More Trustworthy Than FDA or CDC on COVID-19 Vaccine Information, Poll Findshttps://modernod.com/news/americans-see-hospitals-as-more-trustworthy-than-fda-or-cdc-on-covid-19-vaccine-information-poll-finds/2478225/When it comes to getting information about a future COVID-19 vaccine, Americans see hospitals as more trustworthy sources than federal agencies like the Food and Drug Administration or the Centers for Disease Control and Prevention (CDC), according to a new poll, as
- Genentech Initiates Phase 3 Trial for Port Delivery System with Ranibizumab in Diabetic Retinopathyhttps://modernod.com/news/late-stage-trial-starts-for-port-delivery-system-with-ranibizumab-in-diabetic-retinopathy/2478224/Genentech has initiated a new phase 3 clinical trial investigating Port Delivery System with ranibizumab (PDS) for people with diabetic retinopathy (DR). PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customized formulation of r
- Mylan and Biocon Biologics Announce Launch of Semglee in the US for Patients With Diabeteshttps://modernod.com/news/mylan-and-biocon-biologics-announce-launch-of-semglee-in-the-us-for-patients-with-diabetes/2478220/Mylan and Biocon Biologics India announced the US launch of Semglee (insulin glargine injection) in vial and pre-filled pens, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not recommended for the treatment of